The effect of vitamin B6 on anemia

The Comparison of hemoglobin and hematocrit in two groups receiving vitamin B6 and iron with iron in women with iron deficiency anemia referred to health and medical centers of Gonabad city in 1398

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190730044382N1

Enrollment

Registered

2019-08-27

Start date

2019-08-04

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Iron deficiency anemia. Iron deficiency anemia, unspecified

Interventions

Intervention 1: Intervention group will be given 100 mg iron tablets daily (ferrous sulfate) and 80 mg vitamin B6 tablets (pyridoxine hydrochloride manufactured by Iran Hormone Company) for one month.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: MCV <80fl and MCH <and MCHC <33g /dl and ferritin <12mcg / l HB = 8-12gr / dl No history of gastrointestinal bleeding and gastrointestinal surgery and diseases associated with malabsorption including celiac based on patient statement and records No drug and hemoglobin-increasing agents in the last month (blood transfusion, intravenous administration of iron, iron tablets and erythropoietin in the last one month) Lack of any hereditary anemia (including thalassemia and tuberculosis anemia ... based on patient's statement) Lack of chronic disease based on history Not taking other medicines (based on patient's statement or accompanying medication) Not taking supplements, including multivitamins and calcium, on a patient statement No smoking No alcohol or coffee utilization No pregnant

Exclusion criteria

Exclusion criteria: cutt or change medication Not taking iron tablets in the control group and the case even once Not taking vitamin B6 in the case group for even one time Not willing to participate in the study further

Design outcomes

Primary

Measure	Time frame
Percentage of people with increased hemoglobin. Timepoint: At baseline and 30 days after intervention. Method of measurement: To check the complete blood cell count, all women will receive 2 cc of blood in an EDTA vacuum tube and will be tested with the BC5800 CBC manufacturing in 2015.;Percentage of people with increased hematocrit. Timepoint: At baseline and 30 days after intervention. Method of measurement: To check the complete blood cell count, all women will receive 2 cc of blood in an EDTA vacuum tube and will be tested with the BC5800 CBC manufacturing in 2015.	—

Measure

Time frame

Percentage of people with increased hemoglobin. Timepoint: At baseline and 30 days after intervention. Method of measurement: To check the complete blood cell count, all women will receive 2 cc of blood in an EDTA vacuum tube and will be tested with the BC5800 CBC manufacturing in 2015.;Percentage of people with increased hematocrit. Timepoint: At baseline and 30 days after intervention. Method of measurement: To check the complete blood cell count, all women will receive 2 cc of blood in an EDTA vacuum tube and will be tested with the BC5800 CBC manufacturing in 2015.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsma Salar

Gonabad University of Medical Sciences

salar.a.stu@gmu.ac.ir+98 51 5728 8961

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026